Aspira women's health inc. announces receipt of delisting notification from nasdaq

Shelton, ct / access newswire / april 16, 2025 / aspira women's health inc. ("aspira" or the "company") (nasdaq:awh), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that on april 15, 2025, the company received written notice (the "notice") from the office of general counsel of the nasdaq stock market ("nasdaq") indicating that the nasdaq hearings panel has determined to delist the company's shares from nasdaq due to the company's failure to meet nasdaq's continued listing standards. as previously disclosed, the company has not been compliant with the requirements under nasdaq listing rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders' equity for continued listing on the nasdaq capital market.
AWH Ratings Summary
AWH Quant Ranking